Cargando…

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C

BACKGROUND: The detection of baseline resistance mutations to new direct-acting antivirals (DAAs) in HCV chronically infected treatment-naïve patients could be important for their management and outcome prevision. In this study, we investigated the presence of mutations, which have been previously r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costantino, Angela, Spada, Enea, Equestre, Michele, Bruni, Roberto, Tritarelli, Elena, Coppola, Nicola, Sagnelli, Caterina, Sagnelli, Evangelista, Ciccaglione, Anna Rita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650141/ https://www.ncbi.nlm.nih.gov/pubmed/26577836 http://dx.doi.org/10.1186/s12985-015-0414-1

Ejemplares similares

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
por: Sagnelli, Evangelista, et al.
Publicado: (2012)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients
por: Khan, Hafeez Ullah, et al.
Publicado: (2020)

Exploring the inhibitory potential of Nigella sativa against dengue virus NS2B/NS3 protease and NS5 polymerase using computational approaches
por: Mukhtar, Mamuna, et al.
Publicado: (2023)

Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors
por: Kaushik-Basu, Neerja, et al.
Publicado: (2008)

Update on different aspects of HCV variability: focus on NS5B polymerase
por: Marascio, Nadia, et al.
Publicado: (2014)

Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
por: Soumana, Djadé I., et al.
Publicado: (2014)

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2016)

An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones
por: Bruni, Roberto, et al.
Publicado: (2011)

Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic
por: Sagnelli, Caterina, et al.
Publicado: (2021)

Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention
por: Sagnelli, Caterina, et al.
Publicado: (2019)

Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma
por: Sagnelli, Evangelista, et al.
Publicado: (2018)

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
por: Sagnelli, Caterina, et al.
Publicado: (2021)

SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis
por: Sagnelli, Caterina, et al.
Publicado: (2022)

Classification of HCV NS5B Polymerase Inhibitors Using Support Vector Machine
por: Wang, Maolin, et al.
Publicado: (2012)

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
por: Hu, Katherine, et al.
Publicado: (2020)

Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener
por: B, Uma Reddy, et al.
Publicado: (2020)

Microarray analysis identifies a common set of cellular genes modulated by different HCV replicon clones
por: Ciccaglione, Anna Rita, et al.
Publicado: (2008)

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients
por: Sagnelli, Caterina, et al.
Publicado: (2017)

Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease
por: Kumar, Ankur, et al.
Publicado: (2018)

Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2012)

Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays
por: Nutt, Jamie, et al.
Publicado: (2017)

1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
por: Omar, Abdelsattar M., et al.
Publicado: (2020)

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking
por: Karpiński, Tomasz M., et al.
Publicado: (2023)

Discovery of Bispecific Lead Compounds from Azadirachta indica against ZIKA NS2B-NS3 Protease and NS5 RNA Dependent RNA Polymerase Using Molecular Simulations
por: Kumar, Sanjay, et al.
Publicado: (2022)

Engineered Toxins “Zymoxins” Are Activated by the HCV NS3 Protease by Removal of an Inhibitory Protein Domain
por: Shapira, Assaf, et al.
Publicado: (2011)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

Epidemiology and management of hepatitis C virus infections in immigrant populations
por: Coppola, Nicola, et al.
Publicado: (2019)

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2012)

Phosphonate inhibitors of West Nile virus NS2B/NS3 protease
por: Skoreński, Marcin, et al.
Publicado: (2018)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy
por: Dietz, Julia, et al.
Publicado: (2016)

The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region
por: Hamad, Hamzah A., et al.
Publicado: (2016)

Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents
por: Bartolini, Barbara, et al.
Publicado: (2017)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hv4ve2m5jj5q99emgp53lf1iv7